Dasatinib is a safe therapy for imatinib-resistant patients with chronic-phase CML

被引：0
|
作者：
机构：
来源：
Nature Clinical Practice Oncology | 2007年 / 4卷 / 9期
关键词：
D O I：
10.1038/ncponc0891
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：503 / 503
相关论文
共 50 条
  • [31] Long-term safety and efficacy of dasatinib in the treatment of chronic-phase chronic myeloid leukemia patients resistant or intolerant to imatinib
    Shoumariyeh, Khalid
    von Bubnoff, Nikolas
    BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2014, 4 : 81 - 89
  • [32] A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST).
    Trent, J. C.
    Wathen, K.
    von Mehren, M.
    Samuels, B. L.
    Staddon, A. P.
    Choy, E.
    Butrynski, J. E.
    Chugh, R.
    Chow, W. A.
    Rushing, D. A.
    Forscher, C. A.
    Baker, L. H.
    Schuetze, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] Characteristics of Dasatinib- and Imatinib-Resistant Chronic Myelogenous Leukemia Cells
    Okabe, Seiichi
    Tauchi, Tetsuzo
    Ohyashiki, Kazuma
    CLINICAL CANCER RESEARCH, 2008, 14 (19) : 6181 - 6186
  • [34] Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib
    Chuah, Charles
    Melo, Junia V.
    ONCOTARGETS AND THERAPY, 2009, 2 : 83 - 94
  • [35] Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia
    Shah, Neil P.
    Kantarjian, Hagop M.
    Kim, Dong-Wook
    Rea, Delphine
    Dorlhiac-Llacer, Pedro E.
    Milone, Jorge H.
    Vela-Ojeda, Jorge
    Silver, Richard T.
    Khoury, H. Jean
    Charbonnier, Aude
    Khoroshko, Nina
    Paquette, Ronald L.
    Deininger, Michael
    Collins, Robert H.
    Otero, Irma
    Hughes, Timothy
    Bleickardt, Eric
    Strauss, Lewis
    Francis, Stephen
    Hochhaus, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (19) : 3204 - 3212
  • [36] Dasatinib vs imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): DASISION European subpopulation analysis
    Stegelmann, F.
    Mayer, J.
    Warzocha, K.
    Huguet, F.
    Steegmann, J. L.
    Gambacorti-Passerini, C.
    Lofgren, C.
    Dejardin, D.
    Hochhaus, A.
    ONKOLOGIE, 2012, 35 : 47 - 48
  • [37] Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukaemia in chronic phase (CML-CP): updated phase 2 results
    Clark, R.
    Kantarjian, H. M.
    Giles, F. J.
    Hochhaus, A.
    Bhalla, K. N.
    Ossenkoppele, G.
    Gattermann, N.
    Haque, A.
    Gallagher, N.
    Baccarani, M.
    le Coutre, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 : 57 - 58
  • [38] Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
    Kantarjian, Hagop
    Shah, Neil P.
    Hochhaus, Andreas
    Cortes, Jorge
    Shah, Sandip
    Ayala, Manuel
    Moiraghi, Beatriz
    Shen, Zhixiang
    Mayer, Jiri
    Pasquini, Ricardo
    Nakamae, Hirohisa
    Huguet, Francoise
    Boque, Concepcion
    Chuah, Charles
    Bleickardt, Eric
    Bradley-Garelik, M. Brigid
    Zhu, Chao
    Szatrowski, Ted
    Shapiro, David
    Baccarani, Michele
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (24): : 2260 - 2270
  • [39] Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): Updated phase II results
    Kantarjian, H. M.
    Giles, F. J.
    Hochhaus, A.
    Bhalla, K. N.
    Ossenkoppele, G. J.
    Gattermann, N.
    Haque, A.
    Gallagher, N.
    Castagnetti, F.
    le Coutre, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] Dasatinib dose and schedule optimization in chronic-phase CML resistant or intolerant to imatinib: Results from a randomized phase-III trial (CA180034)
    Hochhaus, A.
    Kim, D.-W.
    Rousselot, P.
    Kantarjian, H. M.
    Charbormier, A.
    Heim, D.
    Khoroshko, N.
    Bleickardt, E.
    Francis, S.
    Shah, N. P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 128 - 129
12345